Edge-to-Edge Repair in Cardiogenic Shock

The edge-to-edge approach with MitraClip has been established as a valid strategy for patients who experience severe symptomatic mitral regurgitation (MI) with high risk for surgery, currently with a IIa indication.

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

MI complicated by cardiogenic shock, which results in a high risk for conventional valve surgery, is a particularly complex scenario. In such a case, edge-to-edge repair emerges as an alternative, despite the current lack of exhaustive analyses or randomized studies, with only a handful of publications available.

Researchers conducted a meta-analysis that included 12 studies (7 case series and 5 observational studies) involving 460 patients.

The primary endpoint (PEP) assessed was mortality at one year.

Mean patient age was 68 years; 40% of patients were women. In general, 70% of patients had hypertension, 35% had diabetes, 43% had impaired renal function, 20% had chronic obstructive pulmonary disease (COPD), 11% had a prior stroke, 61% experienced coronary artery disease, and 49% had undergone a prior PCI. Additionally, 21% had undergone previous myocardial revascularization surgery. Ejection fraction was 36%.

Read also: Recurrent Revascularization at 10 Years after Percutaneous Treatment of DES In-Stent Restenosis.

About 74% of patients received inotropics, and a ventricular assist device was used as follows: 28% of patients received an intra-aortic balloon pump (IABP), 29% received an Impella device, and 13% of patients had extracorporeal membrane oxygenation (ECMO).

The most frequent cause of MI was functional (54%), followed by 26% of ischemic origin and 40% resulting from acute myocardial infarction (AMI).

The STS risk index was 17.7%.

The PEP at one year was 36% (95% confidence interval [CI]: 21%–54%), and the presence of MI <2+ was 88% (95% CI: 87%–89%).

Read also: Should We Use Ultrasound Routinely to Guide Transfemoral Access?

Mortality at 30 days was 11% (95% CI: 10%–13%) and 15% at 15 days (95% CI: 13%–16%), with an average hospital stay of 13.9 days (95% CI: 7.08–20.7).

Conclusion

This study is a systematic review and meta-analysis of the clinical features and evolution of edge-to-edge repair in cardiogenic shock in patients with mitral regurgitation. The edge-to-edge approach in mitral regurgitation with cardiogenic shock has been shown to be successful in reducing mitral regurgitation in most patients, although it is associated with a high mortality rate. Randomized controlled studies on edge-to-edge treatment of mitral regurgitation in cardiogenic shock are absolutely imperative.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Mmember of the Editorial Board of SOLACI.org.

Original Title: Transcatheter edge‐to‐edge mitral valve repair for mitral regurgitation in patients with cardiogenic shock: A systematic review and meta‐analysis.

Reference: Tetsuya Saito, et al. Catheter Cardiovasc Interv. 2024;103:340–347.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...